Metfogamma (Metformin Hydrochloride)

Metformin Hydrochloride acts mainly by inhibiting hepatic gluconeogenesis, which reduces the amount of glucose released into the bloodstream. It also enhances peripheral uptake of glucose in muscle and fat tissue and modestly decreases intestinal glucose absorption, collectively improving overall blood‑sugar control.

The dose of Metfogamma is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength, frequency, and titration schedule to achieve optimal glycaemic control.

Safety data for Metfogamma in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To order Metfogamma, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metfogamma (metformin) belongs to the biguanide class and is often first‑line therapy for type 2 diabetes because it does not cause hypoglycaemia when used alone and may promote modest weight loss. In contrast, sulfonylureas increase insulin secretion and carry a higher hypoglycaemia risk, while insulin provides direct glucose lowering but requires injection.

Metfogamma should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. No special refrigeration is required for this oral tablet.

Metfogamma is taken orally, usually with meals to minimise gastrointestinal upset. The tablet is swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their clinician and not crush or split extended‑release formulations unless instructed.

The most serious adverse reaction linked to Metfogamma is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, hypoxia, or excessive alcohol intake. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metfogamma is contraindicated in individuals with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, and in patients with conditions that predispose to hypoxia such as severe heart failure or recent myocardial infarction.